Sanofi: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...
Medscape4d
Trial Shows Dupilumab Reduces Itch, Disease Activity, Steroid Use in Bullous Pemphigoid
Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
Pharmabiz6d
Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD
Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...
S&P 500 Gains and Losses Today: Index Tumbles as Economic Concerns Intensify
The S&P 500 dropped 2.7% on Monday, March 10, as U.S. tariffs and government job cuts heightened economic uncertainty and ...
24/7 Wall St.6d
The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...
The Pharma Letter6d
Dupixent shows promise in treating bullous pemphigoid
Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...